Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
08:00am, Wednesday, 07'th Jul 2021
PALO ALTO, Calif., July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete
PALO ALTO, Calif. , June 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete
Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants
10:53am, Monday, 28'th Jun 2021
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scienti
PALO ALTO, Calif., June 28, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete
Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
04:05pm, Wednesday, 26'th May 2021
PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete
Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q1 2021 Results - Earnings Call Transcript
04:30pm, Sunday, 09'th May 2021
Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q1 2021 Results - Earnings Call Transcript
Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021
08:00am, Thursday, 29'th Apr 2021
PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of target
Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors
08:00am, Thursday, 22'nd Apr 2021
PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of thera
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
04:05pm, Tuesday, 09'th Mar 2021
PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of f
Eiger Pharma: Next Up Is HDV
05:45pm, Sunday, 21'st Feb 2021
EIGR just got approval for progeria. The stock didn't improve much probably because progeria is a minuscule market.
Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
04:28pm, Saturday, 02'nd Jan 2021
Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg a
Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
01:41pm, Monday, 30'th Nov 2020
Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Priority Revi
PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare di
FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know
10:45am, Monday, 23'rd Nov 2020
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-defi
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare di
